{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:44Z","timestamp":1792791944802,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00277-023-05312-4","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T01:01:45Z","timestamp":1686963705000},"page":"2517-2527","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Allogeneic haematopoietic stem cell transplantation for myelofibrosis: prognostic indicators and the role of JAK2V617F measurable-residual disease monitoring by droplet-digital polymerase chain reaction"],"prefix":"10.1007","volume":"102","author":[{"given":"Vivian W.K.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lester","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garret M.K.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelyn","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert K.W.","family":"Lie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yok-Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9551-4893","authenticated-orcid":false,"given":"Harinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"issue":"5","key":"5312_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ajh.25053","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM (2018) Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. Am J Hematol 93(5):649\u2013654. https:\/\/doi.org\/10.1002\/ajh.25053","journal-title":"Am J Hematol"},{"issue":"2","key":"5312_CR2","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.bbmt.2017.09.016","volume":"24","author":"BT Samuelson Bannow","year":"2018","unstructured":"Samuelson Bannow BT, Salit RB, Storer BE, Stevens EA, Wu D, Yeung C, Fang M, Petersdorf EW, Linenberger ML, Woo J, Sorror ML, Doney K, Sandmaier BM, Deeg HJ, Scott BL (2018) Hematopoietic cell transplantation for myelofibrosis: the dynamic international prognostic scoring system plus risk predicts post-transplant outcomes. Biol Blood Marrow Transplant 24(2):386\u2013392. https:\/\/doi.org\/10.1016\/j.bbmt.2017.09.016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"5312_CR3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kroger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC et al (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16(3):358\u2013367. https:\/\/doi.org\/10.1016\/j.bbmt.2009.10.025","journal-title":"Biol Blood Marrow Transplant"},{"key":"5312_CR4","doi-asserted-by":"publisher","first-page":"e871","DOI":"10.1016\/j.jtct.2021.05.016","volume":"27","author":"JP Bewersdorf","year":"2021","unstructured":"Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M (2021) Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis-a systematic review and meta-analysis. Transplant Cell Ther 27:e871. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.016","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"5312_CR5","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32(5):1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"issue":"4","key":"5312_CR6","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M et al (2018) MIPSS70: mutation-enhanced international prognostic score system for transplantation-age patients with primary myelofibrosis. J Clin Oncol 36(4):310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"issue":"17","key":"5312_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, Vannucchi AM (2018) MIPSS70+ Version 2.0: Mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol 36(17):1769\u20131770. https:\/\/doi.org\/10.1200\/JCO.2018.78.9867","journal-title":"J Clin Oncol"},{"issue":"7","key":"5312_CR8","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41375-018-0107-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Begna KH, Naseema G, Pardanani A, Vannucchi AM (2018) GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 32(7):1631\u20131642. https:\/\/doi.org\/10.1038\/s41375-018-0107-z","journal-title":"Leukemia"},{"issue":"8","key":"5312_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-018-0109-0","volume":"8","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM (2018) Myelofibrosis Treatment Algorithm 2018. Blood Cancer J 8(8):72. https:\/\/doi.org\/10.1038\/s41408-018-0109-0","journal-title":"Blood Cancer J"},{"issue":"12","key":"5312_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/ajh.25230","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A (2018) Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management. Am J Hematol 93(12):1551\u20131560. https:\/\/doi.org\/10.1002\/ajh.25230","journal-title":"Am J Hematol"},{"issue":"20","key":"5312_CR11","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1182\/blood-2019-03-900860","volume":"133","author":"F Passamonti","year":"2019","unstructured":"Passamonti F (2019) Stem cell transplant in MF: it\u2019s time to personalize. Blood 133(20):2118\u20132120. https:\/\/doi.org\/10.1182\/blood-2019-03-900860","journal-title":"Blood"},{"issue":"20","key":"5312_CR12","first-page":"2233","volume":"133","author":"N Gagelmann","year":"2019","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Soci\u00e9 G (2019) Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation blood. J Am Soc Hematol 133(20):2233\u20132242","journal-title":"J Am Soc Hematol"},{"issue":"9","key":"5312_CR13","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/s41375-021-01294-2","volume":"35","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Hernandez-Boluda JC, Czerw T, Cross N, Joachim Deeg H, Ditschkowski M, Moonim MT, Polverelli N, Robin M, Aljurf M, Conneally E, Hayden P, Yakoub-Agha I (2021) Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. Leukemia 35(9):2445\u20132459. https:\/\/doi.org\/10.1038\/s41375-021-01294-2","journal-title":"Leukemia"},{"issue":"1","key":"5312_CR14","doi-asserted-by":"publisher","first-page":"103267","DOI":"10.1016\/j.retram.2020.08.003","volume":"69","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Sirait T, Hernandez-Boluda JC, Czerw T, Hayden P, Yakoub-Agha I (2021) European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Curr Res Transl Med 69(1):103267. https:\/\/doi.org\/10.1016\/j.retram.2020.08.003","journal-title":"Curr Res Transl Med"},{"issue":"20","key":"5312_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"issue":"7","key":"5312_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng W-J, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia 36(7):1703\u20131719. https:\/\/doi.org\/10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"issue":"2","key":"5312_CR17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis R, Treatment (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 22(2):437\u2013438. https:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"issue":"11","key":"5312_CR18","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, Shaw BE, Flowers ME, Ruutu T, Greinix H, Holler E, Basak G, Duarte RF, Pavletic SZ, on behalf of the ETCWP, the \u201c ENCGTF (2018) EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl 53(11):1401\u20131415. https:\/\/doi.org\/10.1038\/s41409-018-0204-7","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"5312_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00277-018-3563-7","volume":"98","author":"H Gill","year":"2019","unstructured":"Gill H, Ip H-W, Yim R, Tang W-F, Pang HH, Lee P, Leung GMK, Li J, Tang K, So JCC, Leung RYY, Li J, Panagioutou G, Lam CCK, Kwong Y-L (2019) Next-generation sequencing with a 54-gene panel identified unique mutational profile and prognostic markers in Chinese patients with myelofibrosis. Annals Hematol 98(4):869\u2013879. https:\/\/doi.org\/10.1007\/s00277-018-3563-7","journal-title":"Annals Hematol"},{"issue":"4","key":"5312_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1309\/va755a03pvrv9xdt","volume":"120","author":"WY Au","year":"2003","unstructured":"Au WY, Lam CCK, Lie AKW, Pang A, Kwong YL (2003) T-cell large granular lymphocyte leukemia of donor origin after allogeneic bone marrow transplantation. Am J Clin Pathol 120(4):626\u2013630. https:\/\/doi.org\/10.1309\/va755a03pvrv9xdt","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"5312_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, Hanson CA, Ketterling RP, Pardanani A (2018) Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia 32(5):1189\u20131199. https:\/\/doi.org\/10.1038\/s41375-018-0018-z","journal-title":"Leukemia"},{"issue":"4","key":"5312_CR22","doi-asserted-by":"publisher","first-page":"E103","DOI":"10.1002\/ajh.25037","volume":"93","author":"M Nicolosi","year":"2018","unstructured":"Nicolosi M, Mudireddy M, Patnaik MM, Gangat N, Pardanani A, Tefferi A (2018) A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis. Am J Hematol 93(4):E103\u2013E107. https:\/\/doi.org\/10.1002\/ajh.25037","journal-title":"Am J Hematol"},{"issue":"1","key":"5312_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","volume":"96","author":"A Tefferi","year":"2021","unstructured":"Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96(1):145\u2013162. https:\/\/doi.org\/10.1002\/ajh.26050","journal-title":"Am J Hematol"},{"issue":"26","key":"5312_CR24","doi-asserted-by":"publisher","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T et al (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 114(26):5264\u20135270. https:\/\/doi.org\/10.1182\/blood-2009-07-234880","journal-title":"Blood"},{"issue":"2","key":"5312_CR25","doi-asserted-by":"publisher","first-page":"101369","DOI":"10.1016\/j.beha.2022.101369","volume":"35","author":"JC Hernandez-Boluda","year":"2022","unstructured":"Hernandez-Boluda JC, Czerw T (2022) Transplantation algorithm for myelofibrosis in 2022 and beyond. Best Pract Res Clin Haematol 35(2):101369. https:\/\/doi.org\/10.1016\/j.beha.2022.101369","journal-title":"Best Pract Res Clin Haematol"},{"key":"5312_CR26","doi-asserted-by":"publisher","unstructured":"Alchalby H, Zabelina T, Stubig T, van Biezen A, Bornhauser M, Di Bartolomeo P, Beelen D, Cahn JY, Dreger P, Schroyens W, de Witte T, Olavarria E, Kroger N, Chronic Malignancies Working Party of the European Group for B, Marrow T (2014) Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 20 (2):279-281. doi:https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.027","DOI":"10.1016\/j.bbmt.2013.10.027"},{"issue":"6","key":"5312_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/bmt.2014.31","volume":"49","author":"X Cahu","year":"2014","unstructured":"Cahu X, Chevallier P, Clavert A, Suarez F, Michallet M, Vincent L, Vigouroux S, Blaise D, Mariette C, Bilger K, Robin M, Yakoub-Agha I, Peffault de Latour R, Mohty M (2014) Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transpl 49(6):756\u2013760. https:\/\/doi.org\/10.1038\/bmt.2014.31","journal-title":"Bone Marrow Transpl"},{"key":"5312_CR28","doi-asserted-by":"publisher","first-page":"106821","DOI":"10.1016\/j.leukres.2022.106821","volume":"115","author":"JC Hernandez-Boluda","year":"2022","unstructured":"Hernandez-Boluda JC, Martinez-Cuadron D, Pereira A, Rodriguez-Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martinez-Lopez J, Bergua J, Algarra L, Bernal T, Lopez-Lorenzo JL, Colorado M, Lopez A, Tormo M, Sayas MJ, Trigo F, Lopez-Pavia M et al (2022) Acute leukemia arising from myeloproliferative or myelodysplastic\/myeloproliferative neoplasms: a series of 372 patients from the PETHEMA AML registry. Leukem Res 115:106821. https:\/\/doi.org\/10.1016\/j.leukres.2022.106821","journal-title":"Leukem Res"},{"key":"5312_CR29","doi-asserted-by":"publisher","unstructured":"Gagelmann N, Ditschkowski M, Bogdanov R, Bredin S, Robin M, Cassinat B, Shahswar R, Thol F, Heuser M, Socie G, Beelen D, Triviai I, Badbaran A, Kroger N (2019) Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. https:\/\/doi.org\/10.1182\/blood-2018-12-890889","DOI":"10.1182\/blood-2018-12-890889"},{"key":"5312_CR30","doi-asserted-by":"publisher","unstructured":"Tamari R, Rapaport F, Zhang N, McNamara C, Kuykendall A, Sallman DA, Komrokji R, Arruda A, Najfeld V, Sandy L, Medina J, Litvin R, Famulare CA, Patel MA, Malloy M, Castro-Malaspina H, Giralt S, Weinberg RS, Mascarenhas JO et al (2019) Impact of high-molecular-risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transpl. https:\/\/doi.org\/10.1016\/j.bbmt.2019.01.002","DOI":"10.1016\/j.bbmt.2019.01.002"},{"issue":"2","key":"5312_CR31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbmt.2018.09.001","volume":"25","author":"V Gupta","year":"2019","unstructured":"Gupta V, Kosiorek HE, Mead A, Klisovic RB, Galvin JP, Berenzon D, Yacoub A, Viswabandya A, Mesa RA, Goldberg J, Price L, Salama ME, Weinberg RS, Rampal R, Farnoud N, Dueck AC, Mascarenhas JO, Hoffman R (2019) Ruxolitinib therapy followed by Reduced-intensity conditioning for hematopoietic cell transplantation for myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant 25(2):256\u2013264. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.001","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"5312_CR32","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.bbmt.2018.05.023","volume":"24","author":"N Kroger","year":"2018","unstructured":"Kroger N, Abd Kadir SSS, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C (2018) Peritransplantation ruxolitinib prevents acute graft-versus-host disease in patients with myelofibrosis undergoing allogenic stem cell transplantation. Biol Blood Marrow Transplant 24(10):2152\u20132156. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.023","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5312_CR33","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s12185-022-03340-w","volume":"115","author":"N Gagelmann","year":"2022","unstructured":"Gagelmann N, Kroger N (2022) Improving allogeneic stem cell transplantation in myelofibrosis. Int J Hematol 115(5):619\u2013625. https:\/\/doi.org\/10.1007\/s12185-022-03340-w","journal-title":"Int J Hematol"},{"issue":"3","key":"5312_CR34","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.15407","volume":"182","author":"DP McLornan","year":"2018","unstructured":"McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itala-Remes M, Schaap M, Socie G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ et al (2018) Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Hematol 182(3):418\u2013422. https:\/\/doi.org\/10.1111\/bjh.15407","journal-title":"Br J Hematol"},{"key":"5312_CR35","doi-asserted-by":"publisher","unstructured":"McLornan DP, Yakoub-Agha I, Robin M, Chalandon Y, Harrison CN, Kroger N (2019) State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2018.206151","DOI":"10.3324\/haematol.2018.206151"},{"issue":"18","key":"5312_CR36","first-page":"3572","volume":"116","author":"H Alchalby","year":"2010","unstructured":"Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D, Bornh\u00e4user M, Thiede C, Baurmann H, Bethge W (2010) Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis blood. J Am Soc Hematol 116(18):3572\u20133581","journal-title":"J Am Soc Hematol"},{"issue":"8","key":"5312_CR37","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","volume":"113","author":"N Kroger","year":"2009","unstructured":"Kroger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A (2009) JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 113(8):1866\u20131868. https:\/\/doi.org\/10.1182\/blood-2008-11-190975","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05312-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05312-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05312-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T08:09:26Z","timestamp":1692691766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05312-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["5312"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05312-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"9 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the Institutional Review Board (IRB) of the University of Hong Kong (HKU) (reference number: UW-21-052) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}